ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
MaxCyte Inc

MaxCyte Inc (MXCT)

4.14
0.00
(0.00%)
Cerrado 20 Diciembre 3:00PM
0.00
0.00
(0.00%)
Fuera de horario: -

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Estadísticas y detalles clave

Último Precio
4.14
Postura de Compra
3.96
Postura de Venta
4.33
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
3.165 Rango de 52 semanas 5.545
Capitalización de Mercado [m]
Precio Anterior
4.14
Precio de Apertura
-
Hora
Última hora de negociación
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
532,323
Acciones en circulación
103,504,571
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-11.27
Beneficio por acción (BPA)
-0.37
turnover
41.29M
Beneficio neto
-37.92M

Acerca de MaxCyte Inc

MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds it... MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
Sede
Wilmington, Delaware, USA
Fundado
-
MaxCyte Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker MXCT. The last closing price for MaxCyte was US$4.14. Over the last year, MaxCyte shares have traded in a share price range of US$ 3.165 to US$ 5.545.

MaxCyte currently has 103,504,571 shares in issue. The market capitalisation of MaxCyte is US$428.51 million. MaxCyte has a price to earnings ratio (PE ratio) of -11.27.

MXCT Últimas noticias

MaxCyte Announces Streamlined Operations and Raises 2024 Revenue Guidance

ROCKVILLE, Md., Dec. 08, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the...

MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics

ROCKVILLE, Md., Nov. 13, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...

MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance

ROCKVILLE, Md., Nov. 06, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.17-3.944315545244.314.553.984603884.24713872CS
40.69203.454.553.336841893.82051765CS
120.174.282115869023.974.553.1655323233.69785558CS
26-0.29-6.546275395034.435.1353.1654635153.93854085CS
52-0.86-17.255.5453.1655278234.28494479CS
156-5.79-58.30815709979.9311.0152.455555064.77594138CS
260-12.85-75.632725132416.9917.442.455831675.94169586CS

MXCT - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de MaxCyte?
El precio actual de las acciones de MaxCyte es US$ 4.14
¿Cuántas acciones de MaxCyte están en circulación?
MaxCyte tiene 103,504,571 acciones en circulación
¿Cuál es la capitalización de mercado de MaxCyte?
La capitalización de mercado de MaxCyte es USD 428.51M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de MaxCyte?
MaxCyte ha negociado en un rango de US$ 3.165 a US$ 5.545 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de MaxCyte?
El ratio precio/beneficio de MaxCyte es -11.27
¿Cuál es el ratio de efectivo a ventas de MaxCyte?
El ratio de efectivo a ventas de MaxCyte es 10.35
¿Cuál es la moneda de reporte de MaxCyte?
MaxCyte presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de MaxCyte?
El último ingresos anual de MaxCyte es USD 41.29M
¿Cuál es el último beneficio anual de MaxCyte?
El último beneficio anual de MaxCyte es USD -37.92M
¿Cuál es la dirección registrada de MaxCyte?
La dirección registrada de MaxCyte es 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de MaxCyte?
La dirección del sitio web de MaxCyte es www.maxcyte.com
¿En qué sector industrial opera MaxCyte?
MaxCyte opera en el sector BIOLOGICAL PDS,EX DIAGNSTICS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
AALAmerican Airlines Group Inc
US$ 16.64
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 68.72
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.32
(0.00%)
0
AACGATA Creativity Global
US$ 0.829
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 16.64
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 68.72
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.32
(0.00%)
0
AACGATA Creativity Global
US$ 0.829
(0.00%)
0
AALAmerican Airlines Group Inc
US$ 16.64
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
US$ 0.1326
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
US$ 68.72
(0.00%)
0
AADIAadi Bioscience Inc
US$ 2.32
(0.00%)
0
AACGATA Creativity Global
US$ 0.829
(0.00%)
0
236T568 236T568 46 segundos hace
Very Sad

David Gergen, Adviser To 4 U.S. Presidents, Has Dementia

https://www.huffpost.com/entry/david-gergen-dementia_n_67647dd6e4b00aa16adf512f
rikkie rikkie 2 minutos hace
Look at Polariton and AMF! They have produced world class products in speed, consumption and size. Look at the patents LWLG has collected in photonics and polymers. Don't tell me this will just disappear. I remain optimistic about the polymer "perkinamine" and have higher expectations now that Yves
LWLG
fuagf fuagf 2 minutos hace
My take on all of that is unchanged from the time i arrived in 1967. Australia, like every other country, has bigoted people whether the bigotry is based on ethnicity, imagined race or religion. The antipathy against Israel now is more based on the genocidal posture of the country toward Palesti
Banjo50 Banjo50 12 minutos hace
BIG LOTS FOLDING THE TENT! TOLD YOU SO! COMPLETELY MISMANAGED FOR THE LASR FIVE YEARS!!!
BIGGQ
IVRT IVRT 16 minutos hace
I think the last BMXI carrot is Hall Cadwick. There is no other reason to delay. Cannot replace Hall because the ladder does not go any higher up. The delays have become a millstone around BMXI's neck. Either as you say the audit is fictitious or the audit must be done in January. There are no
BMXI
chereb19 chereb19 31 minutos hace
Isopet has been proven to be profitable
RDGL
QuantumTravesty QuantumTravesty 35 minutos hace
Thanks.
HIRU
knrorrel knrorrel 50 minutos hace
very nice
QNCCF
GASMASK GASMASK 1 hora hace
What's/who's TA?
MRGE
JerryCampbell JerryCampbell 1 hora hace
Data entry error the previous day.

Someone mistakenly entered 8,000,000 instead of 800,000. The -7.2m corrects it.
NWBO
georgejjl georgejjl 1 hora hace
I guess that Anavex could have sales of $14 billion during the first full year after approval in 2026 by the EMA in the EU alone based on capturing a 25% market share of the 8 million people in the EU with Alzheimer’s disease at a prescription cost of $7,000 per year per patient.

Go
AVXL
jeunke22 jeunke22 1 hora hace
Thanks KCC , I am still very positive about my investment here. Doing business implies to understand when it is time to adapt to a given set of circumstances. No need to try to go through a wall, if you can go around it. I think that is what has changed here. A more practical and energetic way to g
LWLG
DMC8 DMC8 1 hora hace
Feeling burnout recently fellow shareholders?

Watch the youtube chat on how to manage burnout by Patrice Bonfiglio, President of Sarissa Capital Management LP.
https://youtu.be/wpFutxLn-wk?si=6Rm2JhCbHvgvUcsb
AMRN
lodas lodas 1 hora hace
jhdf51........never buy a Put or a Call option unless you are 100% sure of the outcome at expiration.... why? you only a 50% chance of success... said another way... you either win, or lose...... however by Selling a Put, or Call options, you have a 66% chance of winning, or 2 ways out of three...
COOP
pepeoil pepeoil 1 hora hace
Good morning shrimpers. Bwahaaaaaa. We are broke. Lol
THEDOG 17 THEDOG 17 2 horas hace
O and you may as well clock out because Bio was acquired!! Yeah if you can’t figure it out maybe you should read that report eagle just posted!!!! Acquisition!!!!! Let’s gooo
jhdf51 jhdf51 2 horas hace
My bird in the hand is COOP. Escrow is now a ROC
capable of carrying hopeful escrowers in its talons.

JHD
COOP
jhdf51 jhdf51 2 horas hace
It seems that people playing options are like people going to Vegas.. they never lose.

JHD
COOP
2018trader 2018trader 2 horas hace
Just keep buying the monopoly 7, I mean mag 7
SPY
TCI1 TCI1 2 horas hace
I can’t open the link to the CVS coverage for 2025, would like to see it as they dropped Vascepa in July.

Sleven have you seen any positive or negative changes?
CVS
TCI1 TCI1 2 horas hace
Well UHC has both IPE and Vascepa covered with PA so you would hope and expect all CVD indications to go to Vascepa. Not sure if this is a change or not but by using a PA UHC are exposing themselves to litigation if they prioritise generic for CVD. Of course this is based off insurers adhering to th
AMRN
Real McCoy Real McCoy 2 horas hace
Yes. In this case the assets were acquired. A long time ago. Right?
THEDOG 17 THEDOG 17 2 horas hace
Sorry I can read !! Obviously you can’t. Acquisition-is that not a real word?
devil dog 96 devil dog 96 2 horas hace
Their O/S has been unchanged since 2021. These guys protect their share structure + they are great at marketing. Can't wait for them to be ready to fire up their next story. She is setup for some silver with how light they have kept her. Heck she has not had an RS since 2009 like 16 years ago and sh
CRSM

Su Consulta Reciente

Delayed Upgrade Clock